Wallace Capital Management Increased General Mls (GIS) Position By $631,074; Last Week Progenics Pharmaceuticals, Inc. (PGNX) Coverage

January 16, 2018 - By Michael Collier

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Friday, October 23. The company was maintained on Wednesday, August 9 by Cantor Fitzgerald. As per Monday, February 6, the company rating was upgraded by Needham. Aegis Capital initiated Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) on Thursday, October 27 with “Buy” rating. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Buy” rating by Jefferies on Tuesday, September 26. Needham maintained the shares of PGNX in report on Friday, August 7 with “Buy” rating. On Tuesday, June 20 the stock rating was maintained by Needham with “Buy”. The firm earned “Buy” rating on Friday, August 7 by Zacks. The firm earned “Buy” rating on Thursday, August 6 by Brean Capital. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Buy” rating by Jefferies on Thursday, June 8. See Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) latest ratings:

26/09/2017 Broker: Jefferies Rating: Buy New Target: $12.0 Maintain
09/08/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $15.0000 Maintain

Wallace Capital Management Inc increased General Mls Inc (GIS) stake by 7.78% reported in 2017Q3 SEC filing. Wallace Capital Management Inc acquired 12,374 shares as General Mls Inc (GIS)’s stock declined 5.07%. The Wallace Capital Management Inc holds 171,385 shares with $8.87 million value, up from 159,011 last quarter. General Mls Inc now has $33.36 billion valuation. The stock increased 1.35% or $0.78 during the last trading session, reaching $58.63. About 2.45 million shares traded. General Mills, Inc. (NYSE:GIS) has declined 10.63% since January 16, 2017 and is downtrending. It has underperformed by 27.33% the S&P500.

The stock decreased 3.94% or $0.25 during the last trading session, reaching $6.09. About 704,747 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since January 16, 2017 and is uptrending. It has outperformed by 31.71% the S&P500.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $427.94 million. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.

Investors sentiment decreased to 1.11 in 2017 Q3. Its down 0.18, from 1.29 in 2017Q2. It worsened, as 22 investors sold Progenics Pharmaceuticals, Inc. shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 58.90 million shares or 4.84% less from 61.90 million shares in 2017Q2 were reported. Rhumbline Advisers holds 0% or 138,707 shares in its portfolio. Natixis stated it has 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). 30,100 are owned by Price T Rowe Associates Md. Teachers Retirement Of The State Of Kentucky holds 0% or 24,000 shares in its portfolio. Blackrock Inc reported 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). 920 were reported by Hall Laurie J Trustee. Barclays Pcl invested 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Fuller & Thaler Asset Mgmt has 444,200 shares. Envestnet Asset Mgmt has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Manufacturers Life Insur Com The owns 61,054 shares for 0% of their portfolio. Parkside Fincl Bank holds 0% or 42 shares in its portfolio. Commercial Bank Of New York Mellon holds 1.06 million shares. State Of Wisconsin Invest Board accumulated 53,000 shares or 0% of the stock. Clarivest Asset Management Ltd reported 186,174 shares. Aqr Capital Mngmt Limited Liability Co invested in 18,012 shares.

Since January 9, 2018, it had 0 insider purchases, and 1 insider sale for $517,458 activity. 8,712 shares were sold by Quam Bethany C., worth $517,458 on Tuesday, January 9.

Investors sentiment decreased to 0.84 in 2017 Q3. Its down 0.16, from 1 in 2017Q2. It turned negative, as 81 investors sold GIS shares while 366 reduced holdings. 62 funds opened positions while 314 raised stakes. 401.33 million shares or 2.97% more from 389.74 million shares in 2017Q2 were reported. Gemmer Asset Mgmt Limited Liability owns 486 shares. The Kentucky-based Teachers Retirement Of The State Of Kentucky has invested 0.04% in General Mills, Inc. (NYSE:GIS). Moreover, Bollard Limited Liability Corporation has 0.14% invested in General Mills, Inc. (NYSE:GIS). Finemark Comml Bank And Tru reported 38,421 shares or 0.13% of all its holdings. Cognios Ltd Liability Corp reported 60,915 shares. Farmers And Merchants Invests stated it has 0.08% of its portfolio in General Mills, Inc. (NYSE:GIS). Sawgrass Asset Management Ltd Llc stated it has 0.07% of its portfolio in General Mills, Inc. (NYSE:GIS). Pggm stated it has 0.23% of its portfolio in General Mills, Inc. (NYSE:GIS). Pictet Asset Mngmt Limited has 0.06% invested in General Mills, Inc. (NYSE:GIS). Tompkins Fin owns 5,706 shares or 0.07% of their US portfolio. Oppenheimer Asset Mgmt has invested 0.19% in General Mills, Inc. (NYSE:GIS). Mogy Joel R Invest Counsel Inc owns 0.09% invested in General Mills, Inc. (NYSE:GIS) for 10,200 shares. Canandaigua Natl Comml Bank has invested 0.28% in General Mills, Inc. (NYSE:GIS). Palo Cap Inc invested in 26,710 shares or 0.73% of the stock. Tradewinds Management Ltd Liability reported 2,605 shares or 0.07% of all its holdings.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>